Dr Reddy’s launches antibiotic drug in US

Tags: News
Indian drug maker Dr Reddy’s has launched a generic and low priced version of the brand Avelox which is under marketing license with Merck. For the US market, the brand has total sales of $195 million at the end of one year in December 2013, estimates IMS Health.

The tablets which have Moxifloxacin Hydrochloride as active ingredient would come in 400 mg form. “Presenty, the competition for the drug is low, with only two other generic players, that is Teva and Aurobindo Pharma with approvals. We expect Dr Reddy’s to post sales of $20 million and net profit $5 million for this drug,” said Sarabjit Kour Nangra, senior vice-president (research, pharma) — Angel Broking.

The anti-infective (bacterial infections) drug contains moxifloxacin which is associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is aggravated in patients above 60 years of age and taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. While Bayer Healthcare manufactures the branded drug, Merck distributes it.

trushnaudgirkar

@mydigitalfc.com

EDITORIAL OF THE DAY

  • Public musn’t pay for domestic servants for our diplomats

    Nothing seems to have changed in the year and half since the fur that flew thick and fast over the case of diplomat Debjani Khobragade and her maid Sa

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

Economic integration in east Asia

As trade agreements within a global framework have become increasingly ...

Rajgopal Nidamboor

Up the ante of your conscious existence

It sounds cryptic, but is not as complex as it ...

Gautam Gupta

The ‘fake’ issue needs to be taken seriously

E-commerce players are witnessing unbelievable growth globally. Competition is increasing ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture